

This spreadsheet enables self-audit of a medicines formulary for adherence to NICE Technology Appraisals. No copyright is asserted if used for non-commercial purposes within the NHS.

Technology appraisal (TA)	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE				
			Yes	N/A	Date of local decision (DD/MM/YY)	Time to implement (days)	Notes (e.g. rationale, method of making available)
2010-11							
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (TA217)	31/03/2011	Donepezil, galantamine, rivastigmine – recommended options for mild and moderate disease. Memantine – a recommended option for moderate disease if people cannot take AChE inhibitors, and for managing severe disease.	x		19/04/2011	19	
Myelodysplastic syndromes - azacitidine (TA218)	31/03/2011	Azacitidine – a recommended option for specified adults not eligible for haematopoietic stem cell transplantation.	x		19/04/2011	19	
Renal cell carcinoma (first line metastatic) - pazopanib (TA215)	28/02/2011	Pazopanib – a recommended option for some people with renal cell carcinoma.	x		15/03/2011	15	
Leukaemia (lymphocytic) - bendamustine (TA216)	28/02/2011	Bendamustine – a recommended option for untreated chronic lymphocytic leukaemia of Binet stage B or C where fludarabine cannot be used.	x		15/03/2011	15	
Schizophrenia - aripiprazole (TA213)	31/01/2011	Aripiprazole – a recommended option in 15 to 17 year olds with schizophrenia if risperidone unresponsive/ unsuitable.	x		15/02/2011	15	
Osteoporosis - primary prevention (TA160)	31/01/2011	As an option to prevent fractures in postmenopausal women with osteoporosis but no fractures: Alendronate – recommended. Risedronate, etidronate – recommended if alendronate not suitable. Strontium ranelate – recommended if bisphosphonates not suitable. Raloxifene – not recommended	x		15/02/2011	15	TA originally added to the formulary in November 2008
Osteoporosis - secondary prevention including strontium ranelate (TA161)	31/01/2011	As an option to prevent fractures in postmenopausal women with osteoporosis who have had fractures: Alendronate – recommended. Risedronate, etidronate – recommended if alendronate not suitable. Strontium ranelate, raloxifene – recommended if bisphosphonates not suitable. Teriparatide – If above options not suitable, or fracture sustained while on bisphosphonates.	x		15/02/2011	15	TA originally added to the formulary in November 2008
Constipation (women) - prucalopride (TA211)	31/12/2010	Prucalopride – recommended as an option for women with chronic constipation after failure of high dose laxatives.	x		18/01/2011	18	

Vascular disease - clopidogrel and dipyridamole (TA210)	31/12/2010	As an option to prevent occlusive vascular events: Clopidogrel – recommended after ischaemic stroke; in peripheral arterial/ multivascular disease; or after MI only if aspirin not suitable. Dipyridamole m/r with aspirin – recommended after a TIA; or after an ischaemic stroke only if clopidogrel unsuitable. Dipyridamole m/r alone – recommended after an ischaemic stroke if aspirin and clopidogrel unsuitable; or after a TIA if aspirin unsuitable.	x		18/01/2011	18	
Gastric cancer (HER2-positive metastatic) - trastuzumab (TA208)	30/11/2010	Trastuzumab – recommended as possible first line treatment for specified types of HER2-positive metastatic gastric adenocarcinoma.	x		18/01/2011	49	
Diabetes (type 2) - liraglutide (TA203)	31/10/2010	Liraglutide – a recommended option at a dose of 1.2 mg daily and no more, with specified oral therapy.	x		16/11/2010	16	
Osteoporotic fractures - denosumab (TA204)	31/10/2010	Denosumab – a recommended option for primary and secondary prevention of fractures in postmenopausal women with osteoporosis if oral bisphosphonates not suitable.	x		16/11/2010	16	
Hepatitis C - peginterferon alfa and ribavirin (TA200)	30/09/2010	Peginterferon alfa (2a or 2b) plus ribavirin – partial update to TA75 and TA106 to broaden the indications for treatment.	x		19/10/2010	19	
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195) Replaces TA36,TA126,TA141	31/08/2010	Rituximab – a recommended option with methotrexate, if inadequate response or intolerance to other DMARDs including at least one TNF inhibitor. Adalimumab, etanercept, infliximab, abatacept – recommended options, with methotrexate, if rituximab contraindicated or not tolerated. Adalimumab, etanercept – recommended monotherapy options if rituximab cannot be given because methotrexate contraindicated or not tolerated.	x		21/09/2010	21	
Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199) Replaces TA104, TA125	31/08/2010	Etanercept, infliximab, adalimumab – recommended for active & progressive psoriatic arthritis, based on specific criteria. Use the least expensive.	x		21/09/2010	21	
Atrial fibrillation - dronedarone (TA197)	31/08/2010	Dronedarone – a recommended option for some people with non-permanent atrial fibrillation.	x		21/09/2010	21	
Lung cancer (non-small-cell, first line) - gefitinib (TA192)	31/07/2010	Gefitinib – a recommended option for first treatment of EGFR-TK mutation positive locally advanced or metastatic non-small-cell lung cancers.	x		17/08/2010	17	
Gastric cancer (advanced) - capecitabine (TA191)	31/07/2010	Capecitabine – recommended with platinum-containing drugs as a first line option for advanced, inoperable stomach cancer.	x		17/08/2010	17	
Leukaemia (chronic lymphocytic, relapsed) - rituximab (TA193)	31/07/2010	Rituximab – a recommended option with fludarabine and cyclophosphamide for some people with relapsed or refractory chronic lymphocytic leukaemia.	x		17/08/2010	17	

Lung cancer (non-small-cell) - pemetrexed (maintenance) (TA190)	30/06/2010	Pemetrexed – a recommended maintenance treatment option for some people with non-small-cell lung cancer.	x		20/07/2010	20	
Human growth hormone (somatropin) for the treatment of growth failure in children (review) (TA188) Replaces TA42	31/05/2010	Growth hormone (somatropin) – a recommended option for some children with growth failure.	x		15/06/2010	15	
Crohn's disease - infliximab (review) and adalimumab (review of TA40) (TA187)	31/05/2010	Infliximab – a recommended option for some people with severe active/ fistulising disease. Adalimumab – a recommended option for some people with severe active disease.	x		15/06/2010	15	
			22	0			
			% "Yes"	% "N/A"	–	Average implement time (days)	
Adherence statistics for 2010-11			100%	0%		19	